Skip to main content

Table 2 Adjusted Odds Ratios with 95% Confidence Intervals for missing stage by patient characteristics, England, 2013

From: Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013

  Cancer patients
  Colon cancer Non-small cell lung cancer Breast cancer
  Model 1a Model 2 b Model 1a Model 2 b Model 1 a Model 2 b
  OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age at diagnosis
 15–64 1   1   1   1   1   1  
 65–74 0.91 (0.80–1.03) 0.78 (0.36–1.71) 0.98 (0.85–1.12) 0.88 (0.48–1.62) 1.13 (0.93–1.36) 1.05 (0.55–2.03)
 75–84 1.13 (1.01–1.28) 1.61 (0.84–3.11) 1.21 (1.05–1.38) 1.10 (0.60–2.01) 1.46 (1.23–1.74) 1.85 (1.06–3.24)
 85+ 1.84 (1.63–2.09) 2.80 (1.43–5.49) 2.08 (1.80–2.39) 2.77 (1.48–5.19) 2.15 (1.80–2.56) 3.71 (2.11–6.49)
Sex
 Male 1   1   1   1      
 Female 1.09 (1.00–1.18) 1.49 (0.97–2.29) 1.05 (0.96–1.15) 1.11 (0.75–1.63)     
Income deprivation group
 More affluent 1   1   1   1   1   1  
 More deprived 0.98 (0.90–1.06) 1.07 (0.70–1.66) 0.91 (0.83–1.00) 1.06 (0.68–1.65) 0.81 (0.72–0.91) 0.92 (0.63–1.35)
Emergency presentation
 No 1   1   1   1   1   1  
 Yes 0.93 (0.84–1.02) 1.01 (0.65–1.57) 0.97 (0.89–1.07) 0.50 (0.31–0.78) 1.24 (1.07–1.45) 1.23 (0.71–2.14)
Death within 30 days of diagnosis
 No 1   1   1   1   1   1  
 Yes 1.63 (1.44–1.85) 1.26 (0.70–2.27) 2.62 (2.37–2.89) 4.91 (3.14–7.69) 1.87 (1.47–2.38) 2.55 (1.14–5.68)
Surgical procedure
 No 1   1   1   1   1   1  
 Yes 0.44 (0.40–0.48) 0.30 (0.19–0.48) 0.68 (0.58–0.79) 0.95 (0.47–1.90) 0.23 (0.20–0.28) 0.31 (0.20–0.49)
Charlson comorbidity index
 0 1   1   1   1   1   1  
 1–2 1.16 (1.05–1.28) 1.40 (0.86–2.29) 1.00 (0.91–1.11) 1.07 (0.69–1.67) 1.08 (0.95–1.24) 0.95 (0.61–1.46)
  > =3 1.34 (1.17–1.53) 1.26 (0.65–2.42) 1.17 (1.03–1.32) 1.01 (0.55–1.84) 1.24 (1.05–1.46) 1.72 (0.98–3.03)
  1. OR odds ratio, 95% CI 95% confidence interval
  2. a Model including the whole sample of patients b Model including only patients in the Clinical Commissioning Groups with high stage completeness